278 results on '"Lockhart, Stephen"'
Search Results
2. Equitable healthcare requires equitable access to nature
3. CLOVER (CLOstridium difficile Vaccine Efficacy tRial) Study: A Phase 3, Randomized Trial Investigating the Efficacy and Safety of a Detoxified Toxin A/B Vaccine in Adults 50 Years and Older at Increased Risk of Clostridioides difficile Infection.
4. Burket's Oral Medicine
5. Phase 3 immunogenicity and safety study of a tick-borne encephalitis vaccine in healthy Japanese participants 1 year of age and older
6. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults
7. A randomized study to evaluate safety and immunogenicity of the BNT162b2 COVID-19 vaccine in healthy Japanese adults
8. Racial and Ethnic Disparities in Opioid Prescribing for Long Bone Fractures at Discharge From the Emergency Department: A Cross-sectional Analysis of 22 Centers From a Health Care Delivery System in Northern California
9. A phase 3 study evaluating the lot consistency, immunogenicity, safety, and tolerability of a Clostridioides difficile vaccine in healthy adults 65 to 85 years of age
10. Carbenes and binaphthyls in asymmetric catalysis
11. Concomitant administration of a fully liquid, ready-to-use DTaP-IPV-HB-PRP-T hexavalent vaccine with a meningococcal serogroup C conjugate vaccine in infants
12. Developing optimal pediatric COVID-19 vaccines for children younger than 12 years during an evolving pandemic
13. A Phase 2 Extension Study Evaluating the Immunogenicity, Safety, and Tolerability of 3 or 4 Doses of a Clostridioides difficile Vaccine in Healthy US Adults Aged 65 to 85 Years
14. A Phase 2 Extension Study Evaluating the Immunogenicity, Safety, and Tolerability of 3 or 4 Doses of a Clostridioides difficile Vaccine in Healthy US Adults Aged 65 to 85 Years.
15. Publisher Correction: Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults
16. Plain language summary for the manuscript: Immune responses to Dose 3 of the BNT162b2 COVID-19 vaccine and its safety in young and older adults
17. Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age
18. Bivalent Omicron BA.1–Adapted BNT162b2 Booster in Adults Older than 55 Years
19. Plain language summary of Pfizer-BioNTech BNT162b2 vaccine protection against COVID-19 and its safety in participants 12- to 15-years-old
20. Plain language summary of Pfizer-BioNTech BNT162b2 COVID-19 vaccine safety in participants 16 years or older and protection against COVID-19 in participants 12 years or older
21. Novel licensure pathways for expeditious introduction of new tuberculosis vaccines: A discussion of the adaptive licensure concept
22. Glycoconjugate Vaccines: The Clinical Journey
23. An Outpatient, Ambulant-Design, Controlled Human Infection Model Using Escalating Doses of Salmonella Typhi Challenge Delivered in Sodium Bicarbonate Solution
24. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial
25. Lessons learnt from the first efficacy trial of a new infant tuberculosis vaccine since BCG
26. Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine
27. Efficacy and safety of the BNT162b2 mRNA COVID-19 vaccine in participants with a history of cancer: subgroup analysis of a global phase 3 randomized clinical trial
28. Immunogenicity and Safety of a Third COVID-19 BNT162b2 mRNA Vaccine Dose in 5- to 11-Year Olds.
29. Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age
30. Immunogenicity and Reactogenicity of Pneumococcal Conjugate Vaccines in Infants and Children
31. Vaccine Clinical Development
32. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months
33. Safety and immunogenicity of a multidose vial formulation of 13-valent pneumococcal conjugate vaccine administered with routine pediatric vaccines in healthy infants in India: A phase 4, randomized, open-label study
34. SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3
35. A clinical trial examining the effect of increased total CRM 197 carrier protein dose on the antibody response to Haemophilus influenzae type b CRM 197 conjugate vaccine
36. Safety and immunogenicity of a 7-valent pneumococcal conjugate vaccine (Prevenar™): Primary dosing series in healthy Chinese infants
37. A phase 4 study of the safety of the 13-valent pneumococcal conjugate vaccine in children 6 to 17 years of age in India
38. Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents
39. Persistence of Disparities Among Racially/Ethnically Marginalized Groups in the Coronavirus Disease 2019 Pandemic Regardless of Statewide Shelter-in-Place Policies: An Analysis From Northern California
40. Measuring and Promoting SARS-CoV-2 Vaccine Equity: Development of a COVID-19 Vaccine Equity Index
41. Altered 5-Hydroxytryptamine Signaling in Patients With Constipation- and Diarrhea-Predominant Irritable Bowel Syndrome
42. Epidemiology of Invasive Escherichia coli Infection and Antibiotic Resistance Status Among Patients Treated in US Hospitals: 2009–2016
43. COVID-19 in pregnancy by race and ethnicity: Implications for development of a vaccination strategy
44. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
45. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
46. Heat Inactivation of Saliva Samples for the Analysis of Cortisol and Cortisone during the COVID-19 Pandemic
47. RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
48. Preventing infectious diseases for healthy ageing: The VITAL public-private partnership project
49. Disparities In Outcomes Among COVID-19 Patients In A Large Health Care System In California
50. Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.